New Mexico Tech University Research Park Corporation

New Mexico Technical Research Foundation

New Mexico Tech Research Foundation

Science & Technology Corporation & Unm

Other

University of New Mexico

Snezna Rogelj

Alexander Kornienko

Liliya Vladlenovna Frolova

Danielle Nicole Turner

Larry A Sklar

Teresa A Bennett

Leslie D Edwards

Kailee Zingler

Cody Champion

Igor V Magedov

Jacob C Greenberg

Robert B Palmer

Pamela Hall

Sean Henry

Charles Melancon

Yasushi Ogasawara

Alexander V Akensov

Gabriel Avilucea

Igov V Magedov

Liam Hallada

Ivy Hurwitz

Alexander Aksenov

Rodolfo Tello-Aburto

Doleshwar Niroula

The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.

Anti-infective formulations

The present disclosure describes a method of treating an infection, including a parasitic infection, using compounds of the invention. The compounds of the invention can selectively eradicate intracellular mammalian and human parasites.

Small molecules with anti-protozoan activity

The disclosure provides proteasome inhibitors that can be used to halt cell division of rapidly dividing cells by preventing the degradation of cell cycle-regulating proteins, such as cyclins, cyclin-dependent kinase inhibitors, and p53. The proteasome inhibitor compounds can be used to inhibit the proliferation of cancer cells.

Proteasome inhibitors

The present disclosure describes a method to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds of the invention can decrease the rate of proliferation of drug-resistant cancer cells, such as glioma, lung cancer, and uterine sarcoma.

Methods for treatment of resistant cancer

The present disclosure describes a method to treat conditions, including bacterial infections and cancer, using a photosensitive compound that, upon exposure to white light, can be activated. The photosensitive compound can also interact synergistically with antibiotics used concomitantly to kill drug-resistant bacteria. The photosensitive compounds can also be used to inhibit the proliferation of cancer cells.

Antibiotic sensitivity-restoring and photosensitive agents

In one aspect, this disclosure describes a pharmaceutical composition that generally includes frankiamicin A and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating a subject having, or at risk of having, a condition caused by a microbial infection treatable with frankiamicin A. Generally, the method includes administering to the subject an amount of frankiamicin A effective to ameliorate at least one symptom or clinical sign of the condition.

Frankiamicin A compositions and methods

A compound having the Formula as follows: wherein R, Rand Rare selected from hydrogen, aryl, fused aryl, heteroaryl, saturated carbocylclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic, Calkyl, haloalkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, alkenylalkyl, alkynylalkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitroalkyl, cyanoalkyl, acetamidoalkyl, and acyloxyalkyl. A process for the preparation thereof is also provided.

Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same

A pharmaceutical composition, a method of producing same, and a method of providing cancer therapy therein comprising a pharmaceutically acceptable excipient or carrier and a compound Formula 3 as follows: or a pharmaceutically acceptable salt or prodrug thereof, wherein:

Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates

A compound having the Formula I as follows: 

A pharmaceutical composition comprising a pharmaceutically acceptable excipient or carrier and a compound Formula I: or a pharmaceutically acceptable salt or prodrug thereof.

Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof

The invention provides anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell, as well as inhibiting lymphocyte traffic through the lymph nodes. The invention further provides an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule.

Inhibition of cell surface protein disulfide isomerase

The invention provides anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell, as well as inhibiting lymphocyte traffic through the lymph nodes. The invention further provides an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule. The invention additionally provides for suppression of inflammation and of lymph node entry by calmodulin antagonists that, like PDI inhibition, cause leukocyte L-selectin shedding.

Growing community of inventors

Socorro, NM, United States of America

Snezna Rogelj